A US district court has said that a key patent held by Astellas on its Myrbetriq drug for urinary incontinence is invalid, in a setback to its efforts to defend the blockbuster therapy from generic ...
Kenji Yasukawa is stepping down as chief executive of Japanese pharma group Astellas, to be succeeded by Naoki Okamura – currently chief strategy officer – on 1st April. Yasukawa is coming to the end ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback